Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma

Melanoma Research

Volumn 23, Issue 1, 2013, Pages 21-26

  Zukauskaite, Ruta ^a   Schmidt, Henrik ^b   Asmussen, Jon T ^a   Hansen, Olfred ^a   Bastholt, Lars ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Asymptomatic brain metastases; Brain metastases; Melanoma

Indexed keywords

INTERLEUKIN 2;

ADOLESCENT; ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; FEMALE; FREQUENCY ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SKIN METASTASIS; STEREOTACTIC RADIOSURGERY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ASYMPTOMATIC DISEASES; BRAIN NEOPLASMS; CHILD; CONTRAST MEDIA; FEMALE; HUMANS; INTERLEUKIN-2; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; RADIOSURGERY; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84872079969     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32835ae915     Document Type: Article

References (37)

1. Lonser RR, Song DK, Klapper J, Hagan M, Auh S, Kerr PB, et al. Surgical management of melanoma brain metastases in patients treated with immunotherapy. J Neurosurg 2011; 115:30-36
2. Hansen LB. Malignant melanoma in Denmark, 1985-1994 [thesis]. Available at: Http://www.melanoma.dk.
3. Raizer JJ, Hwu W-J, Panageas KS,Wilton A, Drew EB, Bailey E. Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features. Neuro Oncol 2008; 10:199-207
4. Majer M, Jensen RL, Shrieve DC,Watson GA,Wang M, Leachman SA, et al. Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Cancer 2007; 110:1329-1337 (Pubitemid 47435606)
5. Martinez SR, Young SE. A rational surgical approach to the treatment of distant melanoma metastases. Cancer Treat Rev 2008; 34:614-620
6. Hong JJ, Rosenberg SA, Dudley ME, Yang JC,White DE, Butman JA, et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res 2010; 16:4892-4898
7. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004; 22:1293-1300 (Pubitemid 41079844)
8. Sampson JH, Carter JH, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998; 88:11-20 (Pubitemid 28018958)
9. Mohr P, Eggermont AMM, Hauschild A, Buzaid A. Staging of cutaneous melanoma. Ann Oncol 2009; 20 (Suppl 6):vi14-vi21
10. Keilholz U, Stoter G, Punt C, Sohneibenbogen C, Lejeune F, Eggermont AMM. Recombinant interleukin-2-based treatments for advanced melanoma: The experience of the european organization for research and treatment of cancer melanoma cooperative group. Cancer J Sci Am 1997; 3 (Suppl 1):S22-S28
11. Vestermark LW, Larsen S, Lindel-Ëv B, Bastholt L. A phase II study of thalidomide in patients with brain metastases from malignant melanoma. Acta Oncol 2008; 47:1526-1530
12. Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma. Cancer 2005; 103:2590-2597 (Pubitemid 40800539)
13. Korn E, Liu P-Y, Lee S. Meta-analysis of phases II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527-534 (Pubitemid 351264344)
14. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler TK, Bamberg M, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010; 102:1213-1218
15. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011; 117:1687-1696
16. Zakrzewski J, Geraghty LN, Rose AE, Christos PJ, Mazumdar M, Polsky D, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 2011; 117:1711-1720
17. Eigentler TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 2011; 117:1697-1703
18. Müller-Horvat C, Radny P, Eigentler TK, Schäfer J, Pfannenberg C, Horger M, et al. Prospective comparison of the impact on treatment decisions of wholebody magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. Eur J Cancer 2006; 42:342-350 (Pubitemid 43132889)
19. Guirguis LM, Yang JC,White DE, Steiberg SM, Liewehr DJ, Rosenberg SA, et al. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother 2002; 25:82-87 (Pubitemid 34052838)
20. Pfannenberg C, Aschoff P, Schanz S, Eschmann SM, Plathow C, Eigentler TK, et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 2007; 43:557-564 (Pubitemid 46177588)
21. Liew DN, Kano H, Kondziolka D, Mathieu D, Niranjan A, Flickinger JC, et al. Outcome predictors of gamma knife surgery for melanoma brain metastases. J Neurosurg 2010; 114:769-779
22. Rao GN, Yu H-HM, Trotti A, Sondak VK. The role of radiation therapy in the management of cutaneous melanoma. Surg Oncol Clin N Am 2011; 20:115-131
23. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol 2004; 22:2101-2107 (Pubitemid 41095143)
24. Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). Eur J Cancer 2011; 47:1476-1483
25. Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K. Single-agent interleukin-2 in the treatment of metastatic melanoma: A systematic review. Cancer Treat Rev 2007; 33:484-496 (Pubitemid 47333669)
26. Powell Stev, Dudek AZ. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer Res 2009; 29:4189-4193
27. Tarhini A, Agarwala SS. Management of brain metastases in patients with melanoma. Curr Opin Oncol 2004; 16:161-166 (Pubitemid 38402531)
28. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723
29. Robert C, Thomas L, Bondarenko I, O'Day S, Jeffrey W, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526
30. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516
31. Heller K, Pavlick A, Hodi F, Thompson J, Margolin KA, Lawrence D. Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases [abstract]. J Clin Oncol 2011; 29 (Suppl):8581
32. Weber J, Amin A, Minor D, Siegel J, Berman D, O'Day S. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: Retrospective analysis of data from a phase 2 trial. Melanoma Res 2011; 21:530-534
33. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: An openlabel, phase 2 trial. Lancet Oncol 2012; 13:459-465
34. Finn L, Markovic S, Joseph R. Therapy for metastatic melanoma: The past, present, and future. BMC Med 2012; 10:1-10
35. Dummer R, Rinderkneckt J, Goldinger S, Wagner I, Mitchell L, Venese M. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. J Clin Oncol 2011; 29 (Suppl):8548
36. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 2012; 379:1893-1901
37. Kirkwood JM, Long GV, Trefzer U, Davies MA, Ascierto P, Chapman PB, et al. BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets) [abstract]. J Clin Oncol 2012; 30 (Suppl):8501